Unity Announces Second Quarter 2024 Financial Results Webcast
Unity Announces Second Quarter 2024 Financial Results Webcast
Unity (NYSE: U) announced today it will release second quarter 2024 financial results after the market close on August 8, 2024, with a webcast to follow at 2 p.m. PT/5 p.m. ET.
The webcast and shareholder letter will be accessible at investors.unity.com. A replay of the webcast will also be available on Unity’s Investor Relations website.
About Unity Software Inc. (Unity)
Unity [NYSE: U] is the world's leading platform of tools for creators to build and grow real-time games, apps, and experiences across multiple platforms, from mobile, PC, and console, to spatial computing. For more information, visit Unity.com.
Unity uses its website (investors.unity.com), filings with the SEC, press releases, social media posts, public conference calls, and public webcasts as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Relations:
ir@unity3d.com
Media Relations:
UnityComms@unity3d.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709144699/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks